Medicalgorithmics

After divesting the US subsidiary Medi-Lynx in 2022, Medicalgorithmics adopted a strategy of becoming a software and platform company, in which core value comes from diagnostic software and AI algorithms rather than the Group's own US diagnostic services. Development is focused on three pillars: the DeepRhythm platform and DeepRhythmAI algorithms, the PocketECG and Kardiobeat.ai devices, and the VCAST software.

In AI and the DRP platform, the goal is to license DRAI algorithms to the largest US IDTFs, medtech partners (Wellysis, Fourth Frontier, CardioScan) and to integrate with third-party devices. The company is broadening DRAI's FDA indications and positioning itself as a "second opinion" tool in digital cardiology.

On the hardware side, the strategy combines sales of the PocketECG system and Kardiobeat.ai device with a licence for the analytical software. The Canadian contract for more than 2,000 Kardiobeat.ai devices (worth about USD 5.9 million) illustrates the target bundle model: hardware, an AI licence and clinical support in a single contract.

The financial targets tied to the 2025-2027 incentive programme are PLN 55 million of revenue in 2025, PLN 60 million in 2026 and PLN 75 million in 2027. The company also signals an ambition to sustain positive EBITDA and operating cash flow, which it achieved for the first time in two years in Q4 2025.